A Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, 3-Period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 micrograms o.d.) in Patients With Moderate to Severe COPD [chronic obstructive pulmonary disease], Using Tiotropium [tiotropium bromide] (18 micrograms o.d.) as an Active Control.

Trial Profile

A Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, 3-Period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 micrograms o.d.) in Patients With Moderate to Severe COPD [chronic obstructive pulmonary disease], Using Tiotropium [tiotropium bromide] (18 micrograms o.d.) as an Active Control.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 05 Nov 2009 Results presented at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
    • 30 Jan 2009 Actual patient numbers (169) added as reported by ClinicalTrials.gov.
    • 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top